Abstract
Human cytomegalovirus (HCMV) is a major pathogen in immunocompromised individuals. Here, non-toxic concentrations of the anti-cancer kinase inhibitor sorafenib were shown to inhibit replication of different HCMV strains (including a ganciclovir-resistant strain) in different cell types. In contrast to established anti-HCMV drugs, sorafenib inhibited HCMV major immediate early promoter activity and HCMV immediate early antigen (IEA) expression. Sorafenib is known to inhibit Raf. Comparison of sorafenib with the MEK inhibitor U0126 suggested that sorafenib inhibits HCMV IEA expression through inhibition of Raf but independently of signaling through the Raf downstream kinase MEK 1/2. In concordance, siRNA-mediated depletion of Raf but not of MEK-reduced IEA expression. In conclusion, sorafenib diminished HCMV replication in clinically relevant concentrations and inhibited HCMV IEA expression, a pathophysiologically relevant event that is not affected by established anti-HCMV drugs. Moreover, we demonstrated for the first time that Raf activation is involved in HCMV IEA expression.
Similar content being viewed by others
References
Sinclair J (2008) Human cytomegalovirus: latency and reactivation in the myeloid lineage. J Clin Virol 41:180–185
Söderberg-Nauclér C (2008) HCMV microinfections in inflammatory diseases and cancer. J Clin Virol 41:218–223
Michaelis M, Doerr HW, Cinatl J Jr (2009) The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia 11:1–9
Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, Gibran NS, Huang ML, Santo Hayes TK, Corey L, Boeckh M (2008) Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 300:413–422
Boeckh M, Ljungman P (2009) How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113:5711–5719
Andrei G, De Clercq E, Snoeck R (2009) Drug targets in cytomegalovirus infection. Infect Disord Drug Targets 9:201–222
Schreiber A, Härter G, Schubert A, Bunjes D, Mertens T, Michel D (2009) Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin Pharmacother 10:191–209
Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P, White K, Corey L, Boeckh M (2003) Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 102:3060–3067
Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J (2003) Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 9:543–558
Mocarski ES Jr, Shenk T, Pass RF (2007) Cytomegalovirus. In: Knipe DM, Howley PM (eds) Fields virology, 5th edn. Lippincott Williams & Wilkins, Philadelphia
Österborg A, Karlsson C, Lundin J, Kimby E, Mellstedt H (2006) Strategies in the management of alemtuzumab-related side effects. Semin Oncol 33:S29–S35
Kuo CP, Wu CL, Ho HT, Chen CG, Liu SI, Lu YT (2008) Detection of cytomegalovirus reactivation in cancer patients receiving chemotherapy. Clin Microbiol Infect 14:221–227
Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, Sampson JH (2008) Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 10:10–18
Lunghi M, Riccomagno P, De Paoli L, Vendramin C, Conconi A, Gaidano G, Rossi D (2009) Monitoring of cytomegalovirus reactivation during induction and nontransplant consolidation of acute leukemia. Am J Hematol 84:697–698
Shanley JD, Debs RJ (1989) The folate antagonist, methotrexate, is a potent inhibitor of murine and human cytomegalovirus in vitro. Antiviral Res 11:99–106
Huang ES, Benson JD, Huong SM, Wilson B, van der Horst C (1992) Irreversible inhibition of human cytomegalovirus replication by topoisomerase II inhibitor, etoposide: a new strategy for the treatment of human cytomegalovirus infection. Antiviral Res 17:17–32
Wachsman M, Hamzeh FM, Saito H, Lietman PS (1996) Anticytomegaloviral activity of methotrexate associated with preferential accumulation of drug by cytomegalovirus-infected cells. Antimicrob Agents Chemother 40:433–436
Strebhardt K, Ullrich A (2008) Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer 8:473–480
Knight ZA, Lin H, Shokat KM (2010) Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 10:130–137
Rodems SM, Spector DH (1998) Extracellular signal-regulated kinase activity is sustained early during human cytomegalovirus infection. J Virol 72:9173–9180
Johnson RA, Ma XL, Yurochko AD, Huang ES (2001) The role of MKK1/2 kinase activity in human cytomegalovirus infection. J Gen Virol 82:493–497
Chen J, Stinski MF (2002) Role of regulatory elements and the MAPK/ERK or p38 MAPK pathways for activation of human cytomegalovirus gene expression. J Virol 76:4873–4885
Prösch S, Staak K, Stein J, Liebenthal C, Stamminger T, Volk HD, Krüger DH (1995) Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNFalpha is mediated via induction of NF-kappaB. Virology 208:197–206
Prösch S, Priemer C, Höflich C, Liebenthaf C, Babel N, Krüger DH, Volk HD (2003) Proteasome inhibitors: a novel tool to suppress human cytomegalovirus replication and virus-induced immune modulation. Antiviral Ther 8:555–567
Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8:33–40
Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550–562
Kudchodkar SB, Yu Y, Maguire TG, Alwine JC (2006) Human cytomegalovirus infection alters the substrate specificities and rapamycin sensitivities of raptor- and rictor-containing complexes. Proc Natl Acad Sci USA 103:14182–14187
Marty FM, Bryar J, Browne SK, Schwarzberg T, Ho VT, Bassett IV, Koreth J, Alyea EP, Soiffer RJ, Cutler CS, Antin JH, Baden LR (2007) Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 110:490–500
Bresnahan WA, Boldogh I, Chi P, Thompson EA, Albrecht T (1997) Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication. Virology 231:239–247
Stein MN, Flaherty KT (2007) CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res 13:3765–3770
Cinatl J Jr, Margraf S, Vogel JU, Scholz M, Cinatl J, Doerr HW (2001) Human cytomegalovirus circumvents NF-kappa B dependence in retinal pigment epithelial cells. J Immunol 167:1900–1908
Schleiss M, Eickhoff J, Auerochs S, Leis M, Abele S, Rechter S, Choi Y, Anderson J, Scott G, Rawlinson W, Michel D, Ensminger S, Klebl B, Stamminger T, Marschall M (2008) Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo. Antiviral Res 79:49–61
Soroceanu L, Akhavan A, Cobbs CS (2008) Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 455:391–395
Michaelis M, Köhler N, Reinisch A, Eikel D, Gravemann U, Doerr HW, Nau H, Cinatl J Jr (2004) Increased human cytomegalovirus replication in fibroblasts after treatment with therapeutical plasma concentrations of valproic acid. Biochem Pharmacol 68:531–538
Michaelis M, Suhan T, Reinisch A, Reisenauer A, Fleckenstein C, Eikel D, Gümbel H, Doerr HW, Nau H, Cinatl J Jr (2005) Increased replication of human cytomegalovirus in retinal pigment epithelial cells by valproic acid depends on histone deacetylase inhibition. Invest Ophthalmol Vis Sci 46:3451–3457
Michaelis M, Ha TA, Doerr HW, Cinatl J Jr (2008) Valproic acid interferes with antiviral treatment in human cytomegalovirus-infected endothelial cells. Cardiovasc Res 77:544–550
Cinatl J Jr, Blaheta R, Bittoova M, Scholz M, Margraf S, Vogel JU, Cinatl J, Doerr HW (2000) Decreased neutrophil adhesion to human cytomegalovirus-infected retinal pigment epithelial cells is mediated by virus-induced up-regulation of Fas ligand independent of neutrophil apoptosis. J Immunol 165:4405–4413
Cinatl J Jr, Michaelis M, Fleckenstein C, Bauer G, Kabicková H, Scholz M, Rabenau HF, Doerr HW (2006) West Nile virus infection induces interferon signalling in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 47:645–651
Romanowski MJ, Shenk T (1997) Characterization of the human cytomegalovirus irs1 and trs1 genes: a second immediate-early transcription unit within irs1 whose product antagonizes transcriptional activation. J Virol 71:1485–1496
Scholz M, Doerr HW, Cinatl J (2001) Inhibition of cytomegalovirus immediate early gene expression: a therapeutic option? Antiviral Res 49:129–145
Cinatl J Jr, Kotchetkov R, Scholz M, Cinatl J, Vogel JU, Driever PH, Doerr HW (1999) Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53. Am J Pathol 155:285–292
Luo MH, Fortunato EA (2007) Long-term infection and shedding of human cytomegalovirus in T98G glioblastoma cells. J Virol 81:10424–10436
Cinatl J Jr, Vogel JU, Kotchetkov R, Scholz M, Doerr HW (1999) Proinflammatory potential of cytomegalovirus infection. specific inhibition of cytomegalovirus immediate-early expression in combination with antioxidants as a novel treatment strategy? Intervirology 42:419–424
Allen LF, Sebolt-Leopold J, Meyer MB (2003) CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 30:105–116
Dai Y, Chen S, Pei XY, Almenara JA, Kramer LB, Venditti CA, Dent P, Grant S (2008) Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood 112:2439–2449
Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127–132
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109
Travi G, Pergam SA, Xie H, Carpenter P, Kiem HP, Corey L, Boeckh MJ (2009) The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation. Clin Infect Dis 49:e120–e123
Blanchet B, Billemont B, Cramard J, Benichou AS, Chhun S, Harcouet L, Ropert S, Dauphin A, Goldwasser F, Tod M (2009) Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal 49:1109–1114
Himmelsbach K, Sauter D, Baumert TF, Ludwig L, Blum HE, Hildt E (2009) New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. Gut 58:1644–1653
Cinatl J Jr, Cinatl J, Vogel JU, Rabenau H, Kornhuber B, Doerr HW (1996) Modulatory effects of human cytomegalovirus infection on malignant properties of cancer cells. Intervirology 39:259–269
Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG, Britt WJ (2002) Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 62:3347–3350
Prins RM, Cloughesy TF, Liau LM (2008) Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 359:539–541
Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R (2008) Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 116:79–86
Strååt K, Liu C, Rahbar A, Zhu Q, Liu L, Wolmer-Solberg N, Lou F, Liu Z, Shen J, Jia J, Kyo S, Björkholm M, Sjöberg J, Söderberg-Nauclér C, Xu D (2009) Activation of telomerase by human cytomegalovirus. J Natl Cancer Inst 101:488–497
Cinatl J Jr, Cinatl J, Vogel JU, Kotchetkov R, Driever PH, Kabickova H, Kornhuber B, Schwabe D, Doerr HW (1998) Persistent human cytomegalovirus infection induces drug resistance and alteration of programmed cell death in human neuroblastoma cells. Cancer Res 58:367–372
Miller G (2009) Brain cancer. A viral link to glioblastoma? Science 323:30–31
Acknowledgments
The authors thank the friendly society “Hilfe für krebskranke Kinder Frankfurt e.V.” and its foundation “Frankfurter Stiftung für krebskranke Kinder” for support. Moreover, the authors thank Mrs. Christina Matreux, Mrs. Gesa Meincke, and Mrs. Ines Tschertner for technical assistance.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Michaelis, M., Paulus, C., Löschmann, N. et al. The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication. Cell. Mol. Life Sci. 68, 1079–1090 (2011). https://doi.org/10.1007/s00018-010-0510-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-010-0510-8